Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The programme could consider the adoption of G6PD testing to allow for the use of either single-dose tafenoquine or higher-dose, shorter-course primaquine, which have been shown to avert more recurrent infections compared to low-dose primaquine [31].”
From Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study (2025) · cites this paper as [31]
In the citing paper
“The tremendous impact of primaquine on reducing the recurrence of P. vivax has been well documented, including in Ethiopia [9, 10, 31].”
From Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study (2025) · cites this paper as [31]
In the citing paper
“Recent multi-country pooled analyses have demonstrated that a high total dose of primaquine (7 mg/kg) provides substantially greater protection against relapse compared with the low-dose (3.5 mg/kg total dose) regimen [8, 9]”
From Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report (2026) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battle, K. E., Lucas, T. C. D., Nguyen, M., Howes, R. E., Nandi, A. K., Twohig, K. A., Pfeffer, D. A., Cameron, E., Rao, P. C., Casey, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31096-7 · Cited by 409
Research works printed but not linked: 49
- Commons, 2020, Estimating the proportion of Plasmodium vivax recurrences caused by relapse: a systematic review and meta-analysis, Am J Trop Med Hyg, 103, 1094, 10.4269/ajtmh.20-0186 · DOI · Paper page
- Thriemer, 2021, Towards the elimination of Plasmodium vivax malaria: implementing the radical cure, PLoS Med, 18, 10.1371/journal.pmed.1003494 · DOI
- Saint-Yves, 1977, Comparison of treatment schedules for Plasmodium vivax infections in the Solomon Islands, P N G Med J, 20, 62
- Krudsood, 2008, High-dose primaquine regimens against relapse of Plasmodium vivax malaria, Am J Trop Med Hyg, 78, 736, 10.4269/ajtmh.2008.78.736 · DOI
- Rajgor, 2014, Antirelapse efficacy of various primaquine regimens for Plasmodium vivax, Malar Res Treat, 2014
- Saravu, 2018, A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in south India, Malar J, 17, 321, 10.1186/s12936-018-2472-5 · doi:10.1186/s12936-018-2472-5
- Pukrittayakamee, 2010, A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand, Am J Trop Med Hyg, 82, 542, 10.4269/ajtmh.2010.09-0428 · doi:10.4269/ajtmh.2010.09-0428
- Chamma-Siqueira, 2022, Higher-dose primaquine to prevent relapse of Plasmodium vivax malaria, N Engl J Med, 386, 1244, 10.1056/NEJMoa2104226 · DOI · Paper page
- Commons, 2017, The Vivax Surveyor: online mapping database for Plasmodium vivax clinical trials, Int J Parasitol Drugs Drug Resist, 7, 181, 10.1016/j.ijpddr.2017.03.003 · DOI
- Taylor, 2019, Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial, Lancet, 394, 929, 10.1016/S0140-6736(19)31285-1 · DOI · Paper page
- Battle, 2014, Geographical variation in Plasmodium vivax relapse, Malar J, 13, 144, 10.1186/1475-2875-13-144 · DOI · Paper page
- Hasugian, 2007, Dihydroartemisinin–piperaquine versus artesunate–amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria, Clin Infect Dis, 44, 1067, 10.1086/512677 · DOI · Paper page
- Barber, 2013, A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy, Clin Infect Dis, 56, 383, 10.1093/cid/cis902 · DOI · Paper page
- Llanos-Cuentas, 2014, Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study, Lancet, 383, 1049, 10.1016/S0140-6736(13)62568-4 · DOI · Paper page
- Pasaribu, 2013, A randomized comparison of dihydroartemisinin–piperaquine and artesunate–amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia, J Infect Dis, 208, 1906, 10.1093/infdis/jit407 · DOI
- Gonzalez-Ceron, 2015, Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico, Malar J, 14, 426, 10.1186/s12936-015-0938-2 · DOI
- Lidia, 2015, Therapeutic effects of dyhidroartemisinin piperaquine versus chloroquine for uncomplicated vivax malaria in Kupang, East Nusa Tenggara, Indonesia, Int J Pharm Sci Rev Res, 31, 247
- Nelwan, 2015, Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia, BMC Med, 13, 294, 10.1186/s12916-015-0535-9 · DOI
- Yuan, 2015, Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar, Antimicrob Agents Chemother, 59, 1230, 10.1128/AAC.04270-14 · DOI · Paper page
- Longley, 2016, High efficacy of primaquine treatment for Plasmodium vivax in western Thailand, Am J Trop Med Hyg, 95, 1086, 10.4269/ajtmh.16-0410 · DOI
- Zuluaga-Idárraga, 2016, Prospective study of Plasmodium vivax malaria recurrence after radical treatment with a chloroquine–primaquine standard regimen in Turbo, Colombia, Antimicrob Agents Chemother, 60, 4610, 10.1128/AAC.00186-16 · DOI
- Abreha, 2017, Comparison of artemether–lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial, PLoS Med, 14, 10.1371/journal.pmed.1002299 · DOI · Paper page
- Awab, 2017, Chloroquine–primaquine versus chloroquine alone to treat vivax malaria in Afghanistan: an open randomized superiority trial, Am J Trop Med Hyg, 97, 1782, 10.4269/ajtmh.17-0290 · DOI · Paper page
- Chu, 2018, Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine–primaquine in Plasmodium vivax malaria, Clin Infect Dis, 67, 1543, 10.1093/cid/ciy319 · DOI · Paper page
- Daher, 2018, Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial, Malar J, 17, 45, 10.1186/s12936-018-2192-x · doi:10.1186/s12936-018-2192-x
- Grigg, 2018, Age-related clinical spectrum of Plasmodium knowlesi malaria and predictors of severity, Clin Infect Dis, 67, 350, 10.1093/cid/ciy065 · DOI
- Chu, 2019, Chloroquine versus dihydroartemisinin–piperaquine with standard high-dose primaquine given either for 7 days or 14 days in Plasmodium vivax malaria, Clin Infect Dis, 68, 1311, 10.1093/cid/ciy735 · DOI
- de Sena, 2019, Doses of chloroquine in the treatment of malaria by Plasmodium vivax in patients between 2 and 14 years of age from the Brazilian Amazon basin, Malar J, 18, 439, 10.1186/s12936-019-3072-8 · DOI
- Lacerda, 2019, Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria, N Engl J Med, 380, 215, 10.1056/NEJMoa1710775 · DOI · Paper page
- Ladeia-Andrade, 2019, Monitoring the efficacy of chloroquine–primaquine therapy for uncomplicated Plasmodium vivax malaria in the main transmission hot spot of Brazil, Antimicrob Agents Chemother, 63, e01965, 10.1128/AAC.01965-18 · DOI · Paper page
- Llanos-Cuentas, 2019, Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria, N Engl J Med, 380, 229, 10.1056/NEJMoa1802537 · DOI · Paper page
- Rijal, 2019, Efficacy of primaquine in preventing short- and long-latency Plasmodium vivax relapses in Nepal, J Infect Dis, 220, 448, 10.1093/infdis/jiz126 · DOI · Paper page
- Thanh, 2015, Confirmed Plasmodium vivax resistance to chloroquine in central Vietnam, Antimicrob Agents Chemother, 59, 7411, 10.1128/AAC.00791-15 · DOI
- Pereira, 2016, Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment, Malar J, 15, 477, 10.1186/s12936-016-1530-0 · DOI
- Edgcomb, 1950, Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report, J Natl Malar Soc, 9, 285
- Pukrittayakamee, 1994, Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria, J Infect Dis, 169, 932, 10.1093/infdis/169.4.932 · DOI
- Bunnag, 1994, High dose of primaquine in primaquine resistant vivax malaria, Trans R Soc Trop Med Hyg, 88, 218, 10.1016/0035-9203(94)90305-0 · doi:10.1016/0035-9203(94)90305-0
- Baird, 2019, 8-aminoquinoline therapy for latent malaria, Clin Microbiol Rev, 32, e00011, 10.1128/CMR.00011-19 · DOI · Paper page
- 2013, The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin–piperaquine: a pooled analysis of individual patient data, PLoS Med, 10
- Barnes, 2006, Sulfadoxine–pyrimethamine pharmacokinetics in malaria: pediatric dosing implications, Clin Pharmacol Ther, 80, 582, 10.1016/j.clpt.2006.08.016 · DOI · Paper page
- Chu, 2021, Determinants of primaquine and carboxyprimaquine exposures in children and adults with Plasmodium vivax malaria, Antimicrob Agents Chemother, 65, 10.1128/AAC.01302-21 · doi:10.1128/aac.01302-21
- Douglas, 2017, Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: a hospital-based cohort study, PLoS Med, 14, 10.1371/journal.pmed.1002379 · DOI · Paper page
- Dinelly, 2021, Evaluation of the effect of supervised anti-malarial treatment on recurrences of Plasmodium vivax malaria, Malar J, 20, 266, 10.1186/s12936-021-03793-0 · DOI
- de Pina-Costa, 2021, Increased primaquine total dose prevents Plasmodium vivax relapses in patients with impaired CYP2D6 activity: report of three cases, Malar J, 20, 341, 10.1186/s12936-021-03869-x · doi:10.1186/s12936-021-03869-x
- Thriemer, 2018, Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group, Malar J, 17, 241, 10.1186/s12936-018-2380-8 · DOI · Paper page
- Clayman, 1952, Toxicity of primaquine in Caucasians, J Am Med Assoc, 149, 1563, 10.1001/jama.1952.72930340022010b · doi:10.1001/jama.1952.72930340022010b
- Chu, 2017, Haemolysis in G6PD heterozygous females treated with primaquine for Plasmodium vivax malaria: a nested cohort in a trial of radical curative regimens, PLoS Med, 14, 10.1371/journal.pmed.1002224 · DOI · Paper page
- Rajasekhar, 2023, Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis, Lancet Infect Dis
- White, 2011, Determinants of relapse periodicity in Plasmodium vivax malaria, Malaria J, 10, 297, 10.1186/1475-2875-10-297 · DOI · Paper page
Cited by
Degaga, T. S., Sime, H., Ruybal-Pesántez, S., Osborne, A., Mwaura, M., Bamboro, S. A., Mnjala, H., Mekonnen, G., Ermias, S., Fantahun, A., et al. (2026) · Malaria Journal · doi:10.1186/s12936-026-06050-4 · Cited by 1
Self-citationShifraw, T., Abdelmenan, S., Zewde, A., Worku, A., Abera, A., Mohammed, H., Etana, K., Keating, J., Chibsa, S., Girma, S., et al. (2025) · Malaria Journal · doi:10.1186/s12936-025-05709-8
Self-citation
Metadata
- Authors
- Commons, R. J., Rajasekhar, M., Edler, P., Abreha, T., Awab, G. R., Baird, J. K., Barber, B. E., Chu, C. S., Cui, L., Daher, A., Gonzalez-Ceron, L., Grigg, M. J., Hwang, J., Karunajeewa, H., Lacerda, M. V. G., Ladeia-Andrade, S., Lidia, K., Llanos-Cuentas, A., Longley, R. J., Pereira, D. B., Pasaribu, A. P., Pukrittayakamee, S., Rijal, K. R., Sutanto, I., Taylor, W. R. J., Thanh, P. V., Thriemer, K., Vieira, J. L. F., Watson, J. A., Zuluaga-Idarraga, L. M., White, N. J., Guerin, P. J., Simpson, J. A., Price, R. N., Adhikari, B., Anstey, N. M., Assefa, A., Boyd, S. C., Chau, N. H., Day, N. P., Degaga, T. S., Dondorp, A. M., Erhart, A., Ferreira, M. U., Ghimire, P., Green, J. A., Koh, G. C., Mekuria, A. H., Mueller, I., Naadim, M. N., Nelwan, E. J., Nosten, F., Price, D. J., Sattabongkot, J., Stepniewska, K., von Seidlein, L., William, T., Woodrow, C. J., & Woyessa, A.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2024-02
- Volume
- 24
- Issue
- 2
- Pages
- 172-183
- ISSN
- 1473-3099
- Cited by
- 61
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- National Health and Medical Research Council (2017436, 2008501, 2016792, 1196068, 1194702)
- Bill & Melinda Gates Foundation
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (093956/Z/10/C, 223253/Z/21/Z)
- Capability Systems Centre
- Centers for Disease Control and Prevention
- Wellcome Trust
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. https://app.cochat.ai/papers/10.1016/s1473-3099(23)00430-9
- The paper
- Commons, R. J., Rajasekhar, M., Edler, P., Abreha, T., Awab, G. R., Baird, J. K., Barber, B. E., Chu, C. S., Cui, L., Daher, A., Gonzalez-Ceron, L., Grigg, M. J., Hwang, J., Karunajeewa, H., Lacerda, M. V. G., Ladeia-Andrade, S., Lidia, K., Llanos-Cuentas, A., Longley, R. J., . . . Woyessa, A. (2024). Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(23)00430-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.